Aspergillus left ventricular assist device endocarditis

Alessandro Barbone, Daniela Pini, Paolo Grossi, Angelo Bandera, Eric Manasse, Enrico Citterio, Alessandro Eusebio, Giuseppe Silvaggio, Fabrizio Settepani, Annamaria Municinò, Piergiuseppe Colombo, Erminia Casari, Diego Ornaghi, Edoardo Gronda, Roberto Gallotti

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Left ventricular assist device (LVAD) support is an established therapy for patients with end-stage heart failure as a bridge to transplant; its usage as an alternative for those patients not eligible for transplant is not an established therapy yet. A 68-year-old male had a Thoratec-Heartmate LVAD implanted as destination therapy. After an uneventful (apart from early fever) recovery in the intensive care unit, the patient developed an intractable high temperature, and generalized sepsis and died 21 days following implant. The white cell blood count never exceeded the guard limits, and the patient succumbed with severe LVAD valve malfunction. At post-mortem examination friable material consisting of fungal hyphae was found on the inflow and outflow valves. According to published clinical trials, infection accounts for more than 40% of mortality in LVAD supported patients. Fungal LVAD endocarditis is a particularly deadly disease. Successful management requires a high level of suspicion and timely institution of antifungal therapy to control the infection. This has led some authors to recommend empiric antifungal therapy in LVAD recipients with culture-negative sepsis unresponsive to broad-spectrum antibiotics.

Original languageEnglish
Pages (from-to)876-880
Number of pages5
JournalItalian Heart Journal
Volume5
Issue number11
Publication statusPublished - Nov 2004

Fingerprint

Heart-Assist Devices
Aspergillus
Endocarditis
Sepsis
Transplants
Therapeutics
Hyphae
Infection Control
Leukocyte Count
Intensive Care Units
Autopsy
Fever
Heart Failure
Clinical Trials
Anti-Bacterial Agents
Temperature
Mortality
Infection

Keywords

  • Fungal infection
  • Heart failure
  • Left ventricular assist device

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Barbone, A., Pini, D., Grossi, P., Bandera, A., Manasse, E., Citterio, E., ... Gallotti, R. (2004). Aspergillus left ventricular assist device endocarditis. Italian Heart Journal, 5(11), 876-880.

Aspergillus left ventricular assist device endocarditis. / Barbone, Alessandro; Pini, Daniela; Grossi, Paolo; Bandera, Angelo; Manasse, Eric; Citterio, Enrico; Eusebio, Alessandro; Silvaggio, Giuseppe; Settepani, Fabrizio; Municinò, Annamaria; Colombo, Piergiuseppe; Casari, Erminia; Ornaghi, Diego; Gronda, Edoardo; Gallotti, Roberto.

In: Italian Heart Journal, Vol. 5, No. 11, 11.2004, p. 876-880.

Research output: Contribution to journalArticle

Barbone, A, Pini, D, Grossi, P, Bandera, A, Manasse, E, Citterio, E, Eusebio, A, Silvaggio, G, Settepani, F, Municinò, A, Colombo, P, Casari, E, Ornaghi, D, Gronda, E & Gallotti, R 2004, 'Aspergillus left ventricular assist device endocarditis', Italian Heart Journal, vol. 5, no. 11, pp. 876-880.
Barbone A, Pini D, Grossi P, Bandera A, Manasse E, Citterio E et al. Aspergillus left ventricular assist device endocarditis. Italian Heart Journal. 2004 Nov;5(11):876-880.
Barbone, Alessandro ; Pini, Daniela ; Grossi, Paolo ; Bandera, Angelo ; Manasse, Eric ; Citterio, Enrico ; Eusebio, Alessandro ; Silvaggio, Giuseppe ; Settepani, Fabrizio ; Municinò, Annamaria ; Colombo, Piergiuseppe ; Casari, Erminia ; Ornaghi, Diego ; Gronda, Edoardo ; Gallotti, Roberto. / Aspergillus left ventricular assist device endocarditis. In: Italian Heart Journal. 2004 ; Vol. 5, No. 11. pp. 876-880.
@article{e7e11535167845c6ad44ecd935970f5a,
title = "Aspergillus left ventricular assist device endocarditis",
abstract = "Left ventricular assist device (LVAD) support is an established therapy for patients with end-stage heart failure as a bridge to transplant; its usage as an alternative for those patients not eligible for transplant is not an established therapy yet. A 68-year-old male had a Thoratec-Heartmate LVAD implanted as destination therapy. After an uneventful (apart from early fever) recovery in the intensive care unit, the patient developed an intractable high temperature, and generalized sepsis and died 21 days following implant. The white cell blood count never exceeded the guard limits, and the patient succumbed with severe LVAD valve malfunction. At post-mortem examination friable material consisting of fungal hyphae was found on the inflow and outflow valves. According to published clinical trials, infection accounts for more than 40{\%} of mortality in LVAD supported patients. Fungal LVAD endocarditis is a particularly deadly disease. Successful management requires a high level of suspicion and timely institution of antifungal therapy to control the infection. This has led some authors to recommend empiric antifungal therapy in LVAD recipients with culture-negative sepsis unresponsive to broad-spectrum antibiotics.",
keywords = "Fungal infection, Heart failure, Left ventricular assist device",
author = "Alessandro Barbone and Daniela Pini and Paolo Grossi and Angelo Bandera and Eric Manasse and Enrico Citterio and Alessandro Eusebio and Giuseppe Silvaggio and Fabrizio Settepani and Annamaria Municin{\`o} and Piergiuseppe Colombo and Erminia Casari and Diego Ornaghi and Edoardo Gronda and Roberto Gallotti",
year = "2004",
month = "11",
language = "English",
volume = "5",
pages = "876--880",
journal = "Italian Heart Journal",
issn = "1129-471X",
publisher = "Societa Italiana di Cardiologia",
number = "11",

}

TY - JOUR

T1 - Aspergillus left ventricular assist device endocarditis

AU - Barbone, Alessandro

AU - Pini, Daniela

AU - Grossi, Paolo

AU - Bandera, Angelo

AU - Manasse, Eric

AU - Citterio, Enrico

AU - Eusebio, Alessandro

AU - Silvaggio, Giuseppe

AU - Settepani, Fabrizio

AU - Municinò, Annamaria

AU - Colombo, Piergiuseppe

AU - Casari, Erminia

AU - Ornaghi, Diego

AU - Gronda, Edoardo

AU - Gallotti, Roberto

PY - 2004/11

Y1 - 2004/11

N2 - Left ventricular assist device (LVAD) support is an established therapy for patients with end-stage heart failure as a bridge to transplant; its usage as an alternative for those patients not eligible for transplant is not an established therapy yet. A 68-year-old male had a Thoratec-Heartmate LVAD implanted as destination therapy. After an uneventful (apart from early fever) recovery in the intensive care unit, the patient developed an intractable high temperature, and generalized sepsis and died 21 days following implant. The white cell blood count never exceeded the guard limits, and the patient succumbed with severe LVAD valve malfunction. At post-mortem examination friable material consisting of fungal hyphae was found on the inflow and outflow valves. According to published clinical trials, infection accounts for more than 40% of mortality in LVAD supported patients. Fungal LVAD endocarditis is a particularly deadly disease. Successful management requires a high level of suspicion and timely institution of antifungal therapy to control the infection. This has led some authors to recommend empiric antifungal therapy in LVAD recipients with culture-negative sepsis unresponsive to broad-spectrum antibiotics.

AB - Left ventricular assist device (LVAD) support is an established therapy for patients with end-stage heart failure as a bridge to transplant; its usage as an alternative for those patients not eligible for transplant is not an established therapy yet. A 68-year-old male had a Thoratec-Heartmate LVAD implanted as destination therapy. After an uneventful (apart from early fever) recovery in the intensive care unit, the patient developed an intractable high temperature, and generalized sepsis and died 21 days following implant. The white cell blood count never exceeded the guard limits, and the patient succumbed with severe LVAD valve malfunction. At post-mortem examination friable material consisting of fungal hyphae was found on the inflow and outflow valves. According to published clinical trials, infection accounts for more than 40% of mortality in LVAD supported patients. Fungal LVAD endocarditis is a particularly deadly disease. Successful management requires a high level of suspicion and timely institution of antifungal therapy to control the infection. This has led some authors to recommend empiric antifungal therapy in LVAD recipients with culture-negative sepsis unresponsive to broad-spectrum antibiotics.

KW - Fungal infection

KW - Heart failure

KW - Left ventricular assist device

UR - http://www.scopus.com/inward/record.url?scp=14844297747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14844297747&partnerID=8YFLogxK

M3 - Article

C2 - 15633446

AN - SCOPUS:14844297747

VL - 5

SP - 876

EP - 880

JO - Italian Heart Journal

JF - Italian Heart Journal

SN - 1129-471X

IS - 11

ER -